<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:chebi fb="0" ids="48120">anthracycline</z:chebi> derivatives are intercalating drugs which are of major importance in the treatment of <z:hpo ids='HP_0001909'>leukemias</z:hpo> and in the management of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Structural analogs have been prepared by semisynthetic modifications in an attempt to extend the spectrum of antitumor activity and to reduce toxicity (<z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> and cardiotoxicity) </plain></SENT>
<SENT sid="2" pm="."><plain>This report concerns our preliminary clinical experience in 111 patients who received detorubicin </plain></SENT>
<SENT sid="3" pm="."><plain>Two dose schedules were used in <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> patients </plain></SENT>
<SENT sid="4" pm="."><plain>Sequential doses were active in <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> relapses but the mucous membrane toxicity was excessive; more recently, intermittent doses proved active in <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> relapses (one 6-mg/kg dose) and in a patient with resistant Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>In non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, a complete response rate of 71% was achieved with an intermittent schedule (3 mg/kg/day X 3 weeks) </plain></SENT>
<SENT sid="6" pm="."><plain>A remarkable shrinkage of skin involvement was also observed </plain></SENT>
<SENT sid="7" pm="."><plain>Detorubicin showed a high activity in <z:e sem="disease" ids="C0026948" disease_type="Neoplastic Process" abbrv="">mycosis fungoides</z:e> (five regressions among six patients) and some activity in soft tissue <z:hpo ids='HP_0100242'>sarcomas</z:hpo>, <z:hpo ids='HP_0002669'>osteosarcomas</z:hpo>, and various <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
</text></document>